Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH® (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH® (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Upcoming Events - Jayson Rieger, PhD, MBA, President and CEO of Verrica, will present at the Jefferies Global Healthcare Conference in New York City [1] - The event is scheduled for June 4, 2025, at 4:20 pm ET [1] - Participants can access a live webcast of the event through the provided link or via the Investors/Presentations & Events section of the Verrica website [2]